SEC Company Response from Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Jan 5, 2010

Altimmune, Inc. (ALT) (CIK 0001326190)
Date: Jan. 5, 2010 · CIK: 0001326190 · Accession: 0001104659-10-000284

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-32587

Referenced dates: December 22, 2009

Date

January 5, 2010

Author

/s/

Form

CORRESP

Company

Altimmune, Inc. (ALT) (CIK 0001326190)

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance PharmAthene, Inc. Form 10-K For the Year Ended December 31, 2008 Form 10-Q For the Quarterly Period Ended September 30, 2009 File No. 001-32587

Dear Mr. Rosenberg, Ms. Mast and Ms. Akins:

By letter dated December 22, 2009, you provided comments on the above-referenced filings of PharmAthene, Inc. (the “Company”). The Company is currently working on the responses to your comments and expects to submit its response letter via EDGAR on or before January 29, 2010.

If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (410) 269-2600 or Jeffrey Baumel or Roland Chase at our outside counsel, Sonnenschein Nath & Rosenthal LLP, at (973) 912-7100.

Sincerely,
/s/
Charles A. Reinhart III

Show Raw Text

CORRESP
1
filename1.htm

[PHARMATHENE LETTERHEAD]

January 5, 2010

VIA
EDGAR

Mr.
Jim B. Rosenberg

Ms.
Mary Mast

Ms.
Tabatha Akins

United
States Securities and Exchange Commission

Division
of Corporation Finance

Mail
Stop 4720

100
F Street, N.E.

Washington,
DC  20549

  Re:

  PharmAthene,
  Inc.

  Form 10-K
  For the Year Ended December 31, 2008

  Form 10-Q
  For the Quarterly Period Ended September 30, 2009

  File No. 001-32587

Dear Mr. Rosenberg, Ms. Mast
and Ms. Akins:

By letter dated December 22,
2009, you provided comments on the above-referenced filings of PharmAthene, Inc.
(the “Company”).  The Company is
currently working on the responses to your comments and expects to submit its
response letter via EDGAR on or before January 29, 2010.

If you have any questions,
or if we may be of any assistance, please do not hesitate to contact the
undersigned at (410) 269-2600 or Jeffrey Baumel or Roland Chase at our outside
counsel, Sonnenschein Nath & Rosenthal LLP, at (973) 912-7100.

  Sincerely,

  /s/
  Charles A. Reinhart III

  Charles
  A. Reinhart III

  Senior Vice President and Chief Financial Officer

Cc:   Jordan P. Karp, Esq.,
Senior Vice President and General Counsel

SecProbe.io